hydralazine has been researched along with Diabetes Mellitus in 12 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge." | 2.82 | Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? ( Bowlin, B; Finch, C; Hartmann, J; Reedus, J; Richardson, A; Sands, CW; Self, T; Tolley, E, 2016) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Tong, ZJ | 1 |
| Kuo, CW | 1 |
| Yen, PC | 1 |
| Lin, CC | 1 |
| Tsai, MT | 1 |
| Lu, SH | 1 |
| Chang, YP | 1 |
| Liu, WS | 1 |
| Tsou, HH | 1 |
| Cheng, HW | 1 |
| Wang, HT | 1 |
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Wong, CM | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Richardson, A | 1 |
| Tolley, E | 1 |
| Hartmann, J | 1 |
| Reedus, J | 1 |
| Bowlin, B | 1 |
| Finch, C | 1 |
| Sands, CW | 1 |
| Self, T | 1 |
| Yoshida, S | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 1 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Kitamura, H | 1 |
| Umemura, S | 1 |
| EVANS, DA | 1 |
| Ishikawa, N | 1 |
| Miyata, T | 1 |
| Kurokawa, K | 1 |
| Kølendorf, K | 1 |
| Bonnevie-Nielsen, V | 1 |
| Broch-Møller, B | 1 |
| Grönvall, JL | 1 |
| Garpenstrand, H | 1 |
| Oreland, L | 1 |
| Ekblom, J | 1 |
| Mogensen, CE | 1 |
| Grenfell, RF | 1 |
| Wójcikiewicz, O | 1 |
| Szopińska-Ciba, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydralazine and Diabetes Mellitus
| Article | Year |
|---|---|
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2004 |
3 trials available for hydralazine and Diabetes Mellitus
8 other studies available for hydralazine and Diabetes Mellitus
| Article | Year |
|---|---|
Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo.
Topics: Acetylcysteine; Acrolein; Animals; Carnosine; Cytokines; Diabetes Mellitus; Diabetic Nephropathies; | 2022 |
Bone morphogenic protein-4-induced oxidant signaling via protein carbonylation for endothelial dysfunction.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Apoptosis; Bone Morphogenetic Protein 4; Cel | 2014 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
CONJOINT CLINIC ON DRUGS AND GENES.
Topics: Acetates; Aminosalicylic Acid; Aminosalicylic Acids; Coenzyme A; Diabetes Mellitus; Genetics, Medica | 1965 |
Autoradiographic imaging of formaldehyde adducts in mice: possible relevance for vascular damage in diabetes.
Topics: Amine Oxidase (Copper-Containing); Animals; Autoradiography; Deamination; Diabetes Mellitus; Enzyme | 1998 |
Diabetes and hypertension.
Topics: Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Furosemide; Glomerular Filtration Rate; H | 1979 |
Treatment of chronic essential hypertension.
Topics: Chlorothiazide; Clonidine; Diabetes Mellitus; Diet, Sodium-Restricted; Gout; Guanethidine; Humans; H | 1977 |
[Effect of nuredal on carbohydrate metabolism in diabetes mellitus].
Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glycosuria; Humans; | 1970 |